Shiyao Group Baike

CSPC Baike (Shandong) Biopharmaceutical is a specialized subsidiary of the CSPC Pharmaceutical Group, focusing on the development and production of innovative biological drugs. The company's flagship product, Jinyouli (pegfilgrastim), is a long-acting recombinant human granulocyte colony-stimulating factor that has become a standard of care in China for preventing chemotherapy-induced neutropenia. CSPC Baike maintains a robust pipeline with a strong emphasis on metabolic diseases and oncology, notably advancing ecnoglutide (TG103), a long-acting GLP-1 receptor agonist, through late-stage clinical trials for diabetes and obesity. The company operates advanced manufacturing facilities in Jinan, Shandong, which are compliant with international GMP standards. As a core component of CSPC's biologics strategy, CSPC Baike plays a pivotal role in the group's transition toward high-value, innovative therapeutic solutions.